Global Information
회사소개 | 문의 | 비교리스트

낭포성 섬유증 치료제 시장 : 세계 산업 동향, 점유율, 규모, 성장률, 기회, 예측(2020-2025년)

Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

리서치사 IMARC Services Private Limited
발행일 2020년 06월 상품 코드 945236
페이지 정보 영문 108 Pages
가격
US $ 2,299 ₩ 2,715,000 PDF (Single User License)
US $ 3,399 ₩ 4,015,000 PDF (5 User License)
US $ 4,499 ₩ 5,314,000 PDF (Corporate License)


낭포성 섬유증 치료제 시장 : 세계 산업 동향, 점유율, 규모, 성장률, 기회, 예측(2020-2025년) Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025
발행일 : 2020년 06월 페이지 정보 : 영문 108 Pages

세계의 낭포성 섬유증 치료제 시장은 2014-2019년 약 15%의 CAGR로 성장했습니다. 낭포성 섬유증(CF)은 소화관과 기도에서 나트륨과 염화물의 이상 동향을 특징으로 하는 진행성 희귀 유전성 질환입니다. 이 질환은 폐, 췌장, 장, 간에서 점성 분비물을 발생시킬 가능성이 있으며, 관리와 치료에는 물리요법, 유전자 치료, 물리치료, 영양 보급 등이 이용됩니다. 또한 췌효소 보충제, 점액용해제, 기관지 확장약, CFTR(cystic fibrosis transmembrane conductance regulator) 조절인자 등의 치료제 및 유전자 치료도 세포의 상호작용 및 증상의 개선을 위해 사용됩니다. CF의 발증률은 세계에서 상승하고 있으며, 질환의 진단 기술 향상과 함께 시장의 성장을 촉진하는 주요 요인입니다. 또한 대체 치료로서 CFTR(cystic fibrosis transmembrane conductance regulator) 조절인자 등 유전자 치료의 보급, 맞춤형 약물 요법, 분자보철의 개발, 유효성이 개선된 혁신적인 약물의 개발 등 기술면의 진보도 시장의 성장을 촉진하는 요인입니다.

세계의 낭포성 섬유증 치료제 시장을 조사했으며, 시장의 개요, 약제 클래스별, 약물 분자 유형별, 투여 경로별, 최종사용자별, 지역별 분석, 업계 및 밸류체인 분석, 가격 지표, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서문

제2장 조사 범위와 방법

제3장 개요

제4장 서론

제5장 세계 시장

  • 시장의 개요
  • 시장 실적

제6장 약제 클래스별 시장 분석

  • 췌효소 보충제
  • 점액용해제
  • 기관지 확장약
  • CFTR 조절인자
  • 항생제
  • 기타

제7장 약물 분자 유형별 시장 분석

  • 저분자약
  • 생물제제

제8장 투여 경로별 시장 분석

  • 경구약
  • 흡입약

제9장 최종사용자별 시장 분석

  • 병원
  • 클리닉
  • 기타

제10장 지역별 시장 분석

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주
    • 인도네시아
    • 기타
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 러시아
    • 기타
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타
  • 중동·아프리카

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter의 산업 분석

제14장 가격 지표

제15장 경쟁 구도

  • 시장 구조
  • 주요 기업
  • 주요 기업 개요
    • Abbvie Inc.
    • Alaxia
    • Alcresta Therapeutics Inc.
    • Allergan
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Vertex Pharmaceuticals Inc.
KSA 20.07.10

List of Figures

  • Figure 1: Global: Cystic Fibrosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Cystic Fibrosis Therapeutics Market: Sales Value (in Billion US$), 2014-2019
  • Figure 3: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Class (in %), 2019
  • Figure 4: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Molecule Type (in %), 2019
  • Figure 5: Global: Cystic Fibrosis Therapeutics Market: Breakup by Route of Administration (in %), 2019
  • Figure 6: Global: Cystic Fibrosis Therapeutics Market: Breakup by End-User (in %), 2019
  • Figure 7: Global: Cystic Fibrosis Therapeutics Market: Breakup by Region (in %), 2019
  • Figure 8: Global: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Billion US$), 2020-2025
  • Figure 9: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 10: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 11: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 12: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 13: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 14: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 15: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 16: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 17: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 18: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 19: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 20: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 21: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 22: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 23: Global: Cystic Fibrosis Therapeutics (Biologics) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 24: Global: Cystic Fibrosis Therapeutics (Biologics) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 25: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 26: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 27: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 28: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 29: Global: Cystic Fibrosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 30: Global: Cystic Fibrosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 31: Global: Cystic Fibrosis Therapeutics (Clinics) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 32: Global: Cystic Fibrosis Therapeutics (Clinics) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 33: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 34: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 35: North America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 36: North America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 37: United States: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 38: United States: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 39: Canada: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 40: Canada: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 41: Asia Pacific: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 42: Asia Pacific: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 43: China: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 44: China: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 45: Japan: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 46: Japan: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 47: India: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 48: India: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 49: South Korea: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 50: South Korea: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 51: Australia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 52: Australia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 53: Indonesia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 54: Indonesia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 55: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 56: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 57: Europe: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 58: Europe: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 59: Germany: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 60: Germany: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 61: France: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 62: France: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 63: United Kingdom: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 64: United Kingdom: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 65: Italy: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 66: Italy: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 67: Spain: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 68: Spain: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 69: Russia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 70: Russia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 71: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 72: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 73: Latin America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 74: Latin America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 75: Brazil: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 76: Brazil: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 77: Mexico: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 78: Mexico: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 79: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 80: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 81: Middle East and Africa: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 82: Middle East and Africa: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 83: Global: Cystic Fibrosis Therapeutics Industry: SWOT Analysis
  • Figure 84: Global: Cystic Fibrosis Therapeutics Industry: Value Chain Analysis
  • Figure 85: Global: Cystic Fibrosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cystic Fibrosis Therapeutics Market: Key Industry Highlights, 2019 and 2025
  • Table 2: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2020-2025
  • Table 3: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Molecule Type (in Million US$), 2020-2025
  • Table 4: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2020-2025
  • Table 5: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by End-User (in Million US$), 2020-2025
  • Table 6: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2020-2025
  • Table 7: Global: Cystic Fibrosis Therapeutics Market Structure
  • Table 8: Global: Cystic Fibrosis Therapeutics Market: Key Players

The global cystic fibrosis therapeutics market grew at a CAGR of around 15% during 2014-2019. Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can cause the development of viscous secretions in the lungs, pancreas, intestines and liver. The management and treatment of CF involve physical therapy, gene therapy, physiotherapy and nutritional support. Along with this, gene therapy and medicinal drugs, such as pancreatic enzyme supplements, mucolytics, bronchodilators and cystic fibrosis transmembrane conductance regulator (CFTR) modulators are also used for targeting cellular interactomes and symptomatic improvement. These drugs can be administered to the patient orally or by inhalation.

The rising incidence of cystic fibrosis across the globe, along with improvements in the diagnostic technologies of the disorder, is one of the key factors driving the growth of the market. Furthermore, widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is also providing a boost to the market growth. CFTRs are configured to regulate the flow of water and chloride through cell linings of the lungs and other organs and correct the malfunctioning protein in the body. Additionally, various technological advancements, such as the development of personalized drug therapy, molecular prosthetics and innovative drugs with improved efficacy, are acting as another growth-inducing factor. Other factors, including rising healthcare expenditures, increasing health consciousness, and awareness regarding the available treatment options for cystic fibrosis, are projected to drive the market further. Looking forward, IMARC Group expects the market to continue to exhibit strong growth during 2020-2025.

Breakup by Drug Class:

  • Pancreatic Enzyme Supplements
  • Mucolytics
  • Bronchodilators
  • CFTR Modulators
  • Antibiotics
  • Others

Breakup by Drug Molecule Type:

  • Small Molecule Drugs
  • Biologics

Breakup by Route of Administration:

  • Oral Drugs
  • Inhaled Drugs

Breakup by End-User:

  • Hospitals
  • Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., etc.

Key Questions Answered in This Report:

  • How has the global cystic fibrosis therapeutics market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the drug molecule type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cystic fibrosis therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Pancreatic Enzyme Supplements
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mucolytics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bronchodilators
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CFTR Modulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Inhaled Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Indicators

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alaxia
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Alcresta Therapeutics Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Allergan
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 AstraZeneca
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Gilead Sciences Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Vertex Pharmaceuticals Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
Back to Top
전화 문의
F A Q